Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders

Hideyuki Iwayama1, Naoko Ishihara2, Kohei Kawahara1, Yuta Madokoro3, Yasuko Togawa4, Kanji Muramatsu4, Ayuka Murakami5,6, Satoshi Kuru5, Toshiyuki Kumagai7,8, Wataru Ohashi9, Kengo Nanya10, Shinji Hasegawa11, Masahisa Katsuno6,12 and Akihisa Okumura1

1Department of Pediatrics, Aichi Medical University School of Medicine, Nagakute, Japan, 2Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan, 3Department of Neurology, Nagoya City University Hospital, Nagoya, Japan, 4Department of Pediatrics, Toyohashi Municipal Hospital, Toyohashi, Japan, 5Department of Neurology, National Hospital Organization Suzuka Hospital, Suzuka, Japan, 6Department of Pediatric Neurology, Aichi Prefectural Colony Central Hospital, Kasugai, Japan, 7Kuma Home Medical Care Clinic, Nagoya, Japan, 8Division of Biostatistics, Clinical Research Center, Aichi Medical University School of Medicine, Nagakute, Japan, 9Clinical Laboratory, Nagoya Memorial Hospital, Nagoya, Japan, 10Department of Pediatrics, Nagoya Memorial Hospital, Nagoya, Japan, 11Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan

Backgrounds: Intramuscular injection of the SARS-CoV-2 vaccine has raised concerns about its use in patients with neuromuscular disorders (NMDs). We evaluated the response of patients with NMDs to the BNT162b2 vaccine.

Methods: Healthy subjects, patients with spinal muscular atrophy (SMA), and patients with Duchenne muscular dystrophy (DMD) were included. All participants received two BNT162b2 doses. SARS-CoV-2 antibody titers at baseline and 2 weeks after each vaccination were compared between groups. Residual muscle volume was evaluated in NMDs group. A questionnaire documented adverse reactions.

Results: Eleven patients with NMDs (9 with SMA, 2 with DMD; 7 males; aged 32.7 ± 19.3 years) and 346 healthy subjects (60 males, aged 40.0 ± 12.4 years) were included. Antibody titers (U/mL) were similar between groups (baseline: <0.40 vs. <0.40, first vaccination, 145 ± 258 vs. 103 ± 1192, and second vaccination, 152 ± 1265 vs. 1429 ± 944; p = 1.000, 0.909, and 0.736, respectively). A negative correlation was found between antibody titers and residual muscle volume but was not significant (Mercuri scale, r = −0.429, p = 0.249; fat infiltration rate, r = −0.194, p = 0.618). The adverse reactions were comparable between groups.
Conclusion: The BNT162b2 vaccine is safe and effective in patients with NMDs.

KEYWORDS
neuromuscular disorders, SARS-CoV-2, vaccination, spinal muscular atrophy, Duchenne muscular dystrophy, residual muscle volume

Introduction

Coronavirus-2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). BNT162b2 is an mRNA-based SARS-CoV-2 vaccine manufactured by Pfizer (1). However, because BNT162b2 is given by intramuscular injection, there is concern about its safety and efficacy in patients with neuromuscular disorders (NMDs).

Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) are rare inherited NMDs that cause muscular atrophy. While individuals with NMDs who are not taking immunosuppressive agents are currently encouraged to receive COVID-19 vaccines (1), only one study has reported the efficacy and safety of the vaccine in these patients (2).

In this study, we aimed to evaluate the safety and efficacy of BNT162b2 in patients with NMDs with muscular atrophy compared to that in healthy subjects. We also examined whether residual muscle volume affects serum levels of the SARS-CoV-2 antibody titer.

Subjects and methods

Ethical compliance

This multi-center prospective observational cohort study was performed in Japan. It was approved by the ethics committee of Aichi Medical University (approval no. 2021-075). All participants provided written informed consent.

Subjects

Employees of Nagoya Memorial Hospital aged 21 years or older were included as healthy subjects (control group). Adolescents or adults aged 12 years or older with SMA or DMD with muscular atrophy who were wheelchair-bound or bedridden were included as patients with NMDs (NMDs group). Diagnoses of NMDs were performed by genetic testing. All participants received two BNT162b2 injections into the deltoid muscle between March and August 2021. We had selected the deltoid muscle because Ministry of Health, Labour and Welfare of Japan recommend that the preferred site was the deltoid muscle of the upper arm (3). Blood was collected from all participants at baseline and two weeks after each dose of the vaccine. Patients with a history of COVID-19 infection or elevated antibody titers prior to vaccination were excluded.

Evaluation

A quantitative determination of antibodies against the receptor binding domain of the SARS-CoV-2 S1 subunit of the spike protein was made using plasma samples at baseline and two weeks after each dose of BNT162b2 (Elecsys anti-SARS-CoV-2 S, Roche Diagnostics International Ltd., Rotkreuz, Switzerland), as previously reported (4). Residual muscle volume was assessed by computed tomography (CT) within 1 year before and after the vaccination date. A slice of CT from the humeral head was obtained to assess the atrophy of the deltoid muscle of each patient using the Mercuri scale (5). CT scans were performed for periodic evaluation of scoliosis and chest deformities, not for the study purpose. We did not select to evaluate the muscular atrophy with echo examination, because we were not familiar with the evaluation of the muscular atrophy with echo examination. The images were blindly evaluated by one reviewer (HI). The muscle and fat were circled using Image J software v. 1.53m (National Institutes of Health) and the each area was measured, as previously reported (6). Fat infiltration rate (FIR) was calculated by dividing the fatty area (cm²) by the total area of the deltoid muscle (cm²). Information on adverse reactions was obtained from participants by questionnaire and classified using the Common Terminology Criteria for Adverse Events v. 4.0. All patients answered the side effect by themselves, not family members. They were not diagnosed with intellectual disability. If the information was missing, the subject was excluded from the evaluation of adverse reactions.

Statistical analysis

Data were expressed as mean ± standard deviation. Qualitative variables were compared using Pearson’s chi-squared tests. The numerical variables in each group,
including antibody titers, were analyzed by student t-tests. The correlations between antibody titers and Mercuri scale and antibody titers and FIR were determined using Pearson correlation tests. The significance level was defined as \( p < 0.05 \).

All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) (7), which is a modified version of R commander, designed to perform statistical functions frequently employed in biostatistics (The R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Participants**

Of the participants, 50 subjects in the healthy control group and one patient with NMDs were excluded due to a history of COVID-19 infection or elevated antibody titers prior to vaccination. Eleven patients with NMDs (SMA, 9; DMD, 2. M: F = 7: 4) and 346 healthy subjects (M: F = 60: 286) were included in the study (Table 1). Seven patients with SMA and two patients with DMD were being treated with nusinersen and viltolarsen, respectively (Table 2). No patients with NMD took any oral steroids or immunosuppressive drugs. CT scans were obtained from nine patients with NMDs. The Mercuri scale grades of the NMDs group were grade 2b (n = 1), grade 3 (n = 4), and grade 4 (n = 4), with a mean FIR of 85.2 ± 16.6%.

**Antibody titers obtained against BNT162b2**

Antibody titers (U/mL) were similar between the NMDs and control groups (baseline: <0.40 vs. <0.40, first vaccination, 145 ± 258 vs. 103 ± 1192, and second vaccination, 1528 ± 1265 vs. 1429 ± 944; \( p = 1.000, 0.909, \) and 0.736, respectively) (Table 1, Figures 1A, B). Although a negative correlation was seen between antibody titers and residual muscle volume, it was not statistically significant either on the Mercuri scale (\( r = -0.429, p = 0.249 \)) or FIR (\( r = -0.194, p = 0.618 \)) (Figures 1C, D). The relationship between the antibody titers two weeks after the first and second vaccination in the NMD group was evaluated, but no correlation was found (\( r = 0.0744, p = 0.828 \)).

When splitting the responses into male and female response, antibody titers two weeks after the first vaccination in males were significantly higher in the NMDs group than in the control group (203 ± 312 vs. 26 ± 29, \( p < 0.001 \)) (Table 1). Antibody titers two weeks after the first vaccination in females were not significantly different between groups (control: 42 ± 69 vs. NMDs: 42 ± 70, \( p = 0.998 \)) (Table 1). Antibody titers two weeks after the second vaccination were not significantly different between healthy and NMD groups for either males or females (M: 1167 ± 633 vs. 1206 ± 990, \( p = 0.886 \); F: 1486 ± 991 vs. 2091 ± 1646, \( p = 0.230 \)) (Table 1).

In the control group, females had significantly higher antibody titers than males after the second vaccination (1st vaccination, M: 26 ± 29 vs. F: 42 ± 69, \( p = 0.0779 \); 2nd vaccination, M: 1167 ± 633 vs. F: 1486 ± 991, \( p = 0.0176 \)), but in the NMD group, female patients did not have significantly higher antibody titers than male patients after either the first or second vaccination (1st vaccination, M: 203 ± 312 vs. F: 42 ± 70, \( p = 0.345 \); 2nd vaccination, M: 1206 ± 990 vs. F: 2091 ± 1646, \( p = 0.287 \)).

**Safety of and adverse reactions caused by BNT162b2**

Due to lack of information, seven of the healthy control subjects were excluded from the evaluation of adverse reactions (Table 3). No anaphylaxis occurred in any of the participants.

| TABLE 1 | Background and SARS-CoV-2 antibody titers of the control and NMDs groups. |
|----------|-----------------|-----------------|-----------------|
| Variables | Control group | NMDs group | \( p \) value |
| N | 346 | 11 (SMA, 9; DMD, 2) | 0.001 |
| Sex (male:female) | 60:286 | 7:4 | 0.062 |
| Age (years) | 40.0 ± 12.4 | 32.7 ± 19.3 | 1.000 |
| SARS-CoV-2 antibody titers (U/mL) | Before vaccination | <0.40 | <0.40 | 0.909 |
| | Two weeks after first vaccination | 103 ± 1192 | 145 ± 258 | <0.001 |
| | Male | 26 ± 29 | 203 ± 312 | 0.998 |
| | Female | 42 ± 69 | 42 ± 70 | 0.736 |
| | Two weeks after second vaccination | 1429 ± 944 | 1528 ± 1265 | 0.886 |
| | Male | 1167 ± 633 | 1206 ± 990 | 0.230 |
| | Female | 1486 ± 991 | 2091 ± 1646 | 0.0176 |

DMD: Duchenne muscular dystrophy; NMDs: neuromuscular disorders; SMA: spinal muscular atrophy; *, In the control group, females had significantly higher antibody titers than males after the second vaccination (\( p = 0.0176 \)).
TABLE 2 Characteristics and residual muscle volume of NMD patients.

| No. | Age | Sex | Disease | Treatment | Mercuri scale | Fat infiltration rate (%) |
|-----|-----|-----|---------|-----------|---------------|--------------------------|
| 1   | 29  | M   | SMA2    | Nusinersen| 4             | 100                      |
| 2   | 26  | F   | SMA2    | Nusinersen| 3             | 76.3                     |
| 3   | 23  | M   | SMA2    | Nusinersen| 4             | 100                      |
| 4   | 42  | M   | SMA2    | Nusinersen| 4             | 100                      |
| 5   | 23  | F   | SMA2    | ND        | ND            | ND                       |
| 6   | 17  | M   | DMD     | Viltolarsen| 2b           | 59.4                     |
| 7   | 20  | M   | DMD     | Viltolarsen| 3             | 61.5                     |
| 8   | 16  | F   | SMA1    | ND        | 4             | 100                      |
| 9   | 65  | M   | SMA3    | Nusinersen| 3             | 87.8                     |
| 10  | 73  | M   | SMA3    | ND        | 3             | 82.0                     |
| 11  | 12  | F   | SMA1    | Nusinersen| ND            | ND                       |

DMD, Duchenne muscular dystrophy; ND, not done; NMDs, neuromuscular disorders; SMA, spinal muscular atrophy.

FIGURE 1
SARS-CoV-2 antibody titers after vaccination. SARS-CoV-2 antibody titers two weeks after the first (A) and second (B) dose of vaccination in healthy controls (n = 346) and patients with neuromuscular disorders (NMDs) (n = 11). Fat infiltration in the deltoid muscle on the Mercuri Scale (C) and fat infiltration rate (D), and SARS-CoV-2 antibody titers after the second dose of vaccination in patients with NMDs.
## Table 3: Adverse reactions observed in the control and NMD groups.

| Adverse reactions        | After the first vaccination |                           | p value | After the second vaccination |                           | p value |
|--------------------------|----------------------------|----------------------------|---------|------------------------------|----------------------------|---------|
|                          | Control group (n = 339)    | NMDs group (n = 11)        |         | Control group (n = 339)     | NMDs group (n = 11)        |         |
| Any adverse reactions    |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 329 (97.1%)                | 8 (72.7%)                  | 0.0007  | 329 (97.1%)                  | 8 (72.7%)                  | 0.0007  |
| ≥grade 2                 | 61 (18.0%)                 | 0 (0%)                     | 0.2524  | 113 (33.3%)                  | 3 (27.2%)                  | 0.9244  |
| ≥grade 3                 | 5 (1.5%)                   | 0 (0%)                     | 1.000   | 6 (1.8%)                     | 0 (0%)                     | 1.000   |
| Anaphylaxis              | 0 (0%)                     | 0 (0%)                     | 1.000   | 0 (0%)                       | 0 (0%)                     | 1.000   |
| Vasovagal reflex         | 0 (0%)                     | 0 (0%)                     | 1.000   | 1 (0.3%)                     | 0 (0%)                     | 1.000   |
| Injection site reaction  |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 271 (80.0%)                | 7 (63.6%)                  | 0.3484  | 310 (91.4%)                  | 5 (45.5%)                  | <0.0001 |
| ≥grade 2                 | 45 (13.3%)                 | 0 (0%)                     | 0.1955  | 25 (7.4%)                    | 0 (0%)                     | 0.7339  |
| ≥grade 3                 | 1 (0.3%)                   | 0 (0%)                     | 1.000   | 1 (0.3%)                     | 0 (0%)                     | 1.000   |
| Fatigue                  |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 62 (18.3%)                 | 1 (9.1%)                   | 0.7019  | 184 (54.3%)                  | 5 (45.5%)                  | 0.7868  |
| ≥grade 2                 | 11 (3.2%)                  | 0 (0%)                     | 1.000   | 65 (19.2%)                   | 2 (18.2%)                  | 1.000   |
| ≥grade 3                 | 2 (0.6%)                   | 0 (0%)                     | 1.000   | 2 (0.6%)                     | 0 (0%)                     | 1.000   |
| Headache                 |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 54 (15.9%)                 | 1 (9.1%)                   | 0.8474  | 151 (44.5%)                  | 3 (27.2%)                  | 0.4082  |
| ≥grade 2                 | 8 (2.4%)                   | 0 (0%)                     | 1.000   | 34 (10.0%)                   | 0 (0%)                     | 0.5564  |
| ≥grade 3                 | 1 (0.3%)                   | 0 (0%)                     | 1.000   | 1 (0.3%)                     | 0 (0%)                     | 1.000   |
| Fever                    |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 4 (1.2%)                   | 0 (0%)                     | 1.000   | 71 (20.9%)                   | 1 (9.1%)                   | 0.5631  |
| ≥grade 2                 | 3 (0.9%)                   | 0 (0%)                     | 1.000   | 18 (5.3%)                    | 1 (9.1%)                   | 1.000   |
| ≥grade 3                 | 0 (0%)                     | 0 (0%)                     | 1.000   | 1 (0.3%)                     | 0 (0%)                     | 1.000   |
| Chills                   |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 3 (0.9%)                   | 0 (0%)                     | 1.000   | 35 (10.3%)                   | 0 (0%)                     | 0.5401  |
| ≥grade 2                 | 0 (0%)                     | 0 (0%)                     | 1.000   | 22 (6.5%)                    | 0 (0%)                     | 0.8091  |
| Myalgia                  |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 80 (23.6%)                 | 5 (45.5%)                  | 0.1914  | 134 (39.5%)                  | 5 (45.5%)                  | 0.9344  |
| ≥grade 2                 | 9 (2.7%)                   | 0 (0%)                     | 1.000   | 24 (7.1%)                    | 0 (0%)                     | 0.7579  |
| ≥grade 3                 | 2 (0.6%)                   | 0 (0%)                     | 1.000   | 2 (0.6%)                     | 0 (0%)                     | 1.000   |
| Arthralgia               |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 29 (8.6%)                  | 0 (0%)                     | 0.6475  | 108 (31.9%)                  | 2 (18.2%)                  | 0.5276  |
| ≥grade 2                 | 2 (0.6%)                   | 0 (0%)                     | 1.000   | 27 (8.0%)                    | 0 (0%)                     | 0.689   |
| ≥grade 3                 | 0 (0%)                     | 0 (0%)                     | 1.000   | 2 (0.6%)                     | 0 (0%)                     | 1.000   |
| Diarrhea                 |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 13 (3.8%)                  | 0 (0%)                     | 1.000   | 18 (5.3%)                    | 0 (0%)                     | 0.9274  |
| ≥grade 2                 | 2 (0.6%)                   | 0 (0%)                     | 1.000   | 4 (1.2%)                     | 0 (0%)                     | 1.000   |
| Nausea                   |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 11 (3.2%)                  | 0 (0%)                     | 1.000   | 41 (12.1%)                   | 1 (9.1%)                   | 1.000   |
| ≥grade 2                 | 5 (1.5%)                   | 0 (0%)                     | 1.000   | 13 (3.8%)                    | 0 (0%)                     | 1.000   |
| ≥grade 3                 | 1 (0.3%)                   | 0 (0%)                     | 1.000   | 0 (0%)                       | 0 (0%)                     | 1.000   |
| Vomiting                 |                            |                            |         |                              |                            |         |
| ≥grade 1                 | 7 (2.1%)                   | 0 (0%)                     | 1.000   | 7 (2.1%)                     | 0 (0%)                     | 1.000   |
| ≥grade 2                 | 5 (1.5%)                   | 0 (0%)                     | 1.000   | 3 (0.9%)                     | 0 (0%)                     | 1.000   |
| ≥grade 3                 | 2 (0.6%)                   | 0 (0%)                     | 1.000   | 0 (0%)                       | 0 (0%)                     | 1.000   |
| Use of analgesics        | 41 (12.1%)                 | 3 (27.2%)                  | 0.3019  | 193 (56.9%)                  | 2 (18.2%)                  | 0.0252  |

NMDs, neuromuscular disorders.

Grades not listed in the table were not observed in patients in either group.
Vasovagal reflex occurred in one participant in the control group after the second vaccination. The frequency of any adverse reactions ≥ grade 1 was lower in the NMDs group than in the control group after each dose of the vaccine, but the frequency of any adverse reactions ≥ grade 2 or 3 was comparable between the groups (first vaccination: grade 1, p = 0.0007; grade 2, p = 0.2524; grade 3, p = 0.685 and second vaccination: grade 1, p = 0.0007; grade 2, p = 0.9244; grade 3, p = 1.000) (Table 3). The frequency of injection site reaction was similar in both the groups during the first vaccination; however, it was lower in the NMDs group than in the control group during the second vaccination (first vaccination, p = 0.3484; second vaccination, p < 0.0001). Other side effects and grades were similar among the groups. Furthermore, the frequency of analgesic use was similar in both the groups during the first vaccination, whereas it was lower in the NMDs group than in the control group during the second vaccination (first vaccination, p = 0.3019; second vaccination, p = 0.0252).

A 73-year-old patient with SMA developed blisters a few days after the first dose of BNT162b2. He was diagnosed with bullous pemphigoid due to the positive BP180 antibody and treated with 15 mg of prednisolone.

**Discussion**

This study showed the efficacy and safety of BNT162b2 in patients with NMDs. These patients were found to have antibody titers similar to those of healthy controls after intramuscular vaccination. The frequency of adverse reactions was lower in the NMDs group than in the control group.

**Vaccination in NMDs**

As there was no information on mRNA vaccines, the vaccine was administered via intramuscular injection in the BNT162b2 trial. Intramuscular administration of vaccines into the deltoid optimizes the immunogenicity of the vaccine and minimizes adverse reactions at the injection site (8). Muscles have good vascularity and therefore allow the injected drug to reach the systemic circulation quickly, bypassing the first-pass metabolism (9). Injecting a vaccine into subcutaneous fat has been reported to cause vaccine failure in hepatitis B, rabies, and influenza vaccines (8). One study compared the immunogenicity of intramuscular versus subcutaneous administration with inactivated influenza vaccine in NMDs (10). There is a review article related to the vaccination in neurological disease, including muscular dystrophy and spinal muscular atrophy (11). However, there were no existing guidelines/recommendations for the vaccination for NMDs.

**Efficacy of BNT162b2 in NMDs**

In this study, the antibody titers in the NMDs group were similar to those in the control group two weeks after each dose of the vaccine. Similar to our results, one paper reported increased antibody titers with BNT162b2 in patients with advanced neuromuscular disease (2). Although the patients with NMDs in this study had marked muscular atrophy and muscle had been replaced by fat, vascular tissue may be preserved even in atrophied muscle. Serum levels of antibody titers were found to be negatively correlated with residual muscle volume, but this correlation did not reach statistical significance. However, it is possible that this was due to the small number of patients in the NMDs group in this study. Previous report has not investigated the relationship between muscle remnants and increased antibody titers (2). The presence of a similar immune response to BNT162b2 indicates the non-muscle components as being more critical for immune response to mRNA vaccination. We tentatively conclude that, although the COVID-19 vaccine is administered to fat-replaced muscle, the COVID-19 vaccine may increase antibody titers sufficiently via preserved vascular tissue. Therefore, BNT162b2 appears to be effective in patients with NMDs.

**Safety of BNT162b2 in NMDs**

In the present study, the frequency of any adverse reactions ≥ grade 1 was lower in the NMDs group than in the control group after each dose of the vaccine, but the frequency of any adverse reactions ≥ grade 2 or 3 was comparable between the groups. This difference in the frequency of adverse reactions observed in each group may be attributed to the definition of the grade of adverse reactions. Grade 2 is defined as having symptoms and limitations in performing age-related instrumental activities of daily living. Because patients with NMDs did not perform many activities of daily living, they were possibly less informed about the symptoms of adverse reactions and did not have difficulties in their daily life. The lower frequency of analgesic use in the NMDs group after the second vaccination indicated that patients with NMDs did not have severe adverse reactions to vaccines. Therefore, BNT162b2 appears to be safe for use in patients with NMDs.

Previous research has found that several patients have developed bullous pemphigoid after vaccination with BNT162b2 (12). All five cases of bullous pemphigoid were found to have positive BP180 antibodies and developed symptoms after the second dose of vaccination. In this study, a patient with SMA developed bullous pemphigoid a few days after the first dose of BNT162b2. Therefore, the bullous pemphigoid in this patient was not considered to be an adverse reaction to BNT162b2 because it developed after the first dose of BNT162b2, rather than the second.
Limitations of this study

This study was limited by the sample size of patients with NMDs, short follow-up period, and a lack of confirmation of the vaccination site. As the facility for NMDs and that for the vaccination were different, we could not confirm the vaccination site with ultrasound. Although it was reported that antibody titers after vaccination with BNT162b2 were significantly higher in females than in males (13), the gender impact on antibody titers was not evident in the NMDs group of this study. Larger studies with longer follow-ups are necessary to establish the efficacy and safety of BNT162b2 in this population.

Conclusion

Antibody titers in patients with NMDs were similar to those of healthy controls and there was no difference in the percentage of adverse reactions to BNT162b2 between the NMDs group and healthy controls. Although BNT162b2 is administered by intramuscular injection, it appears to be effective and safe in patients with NMDs.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the ethics committee of Aichi Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

HI contributed to the study design, interpretation of data, and was a major contributor in writing the manuscript. NI, KK, YM, YT, KM, AM, SK, TK, WO, and KN contributed to the acquisition and analysis of data from the patients. SH, MK, AO, and HI revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funding

The research of HI was supported by JSPS KAKENHI, Grant No. 21K07783. The research of AO was supported by JSPS KAKENHI, Grant No. 21K07810.

Acknowledgments

We acknowledge the assistance of ENAGO with the English language editing.

Conflict of interest

Author MK received royalties more than 1,000,000 yen from Takeda Pharmaceutical Company.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Živković SA, Graemer G, Narayanaswami P. Doctor should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders. Muscle Nerve. (2021) 63:294–303. doi: 10.1002/mus.27179
2. Demonbreun AR, Velez MP, Saber R, Ryan DT, Sancilio A, McDade TW, et al. mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease. Neuromuscul Disord (2022) 32:33–5. doi: 10.1016/j.nmd.2021.11.006
3. Ministry of Health, Labour and Welfare of Japan. Annex i summary of product characteristics. Available at: https://www.mhlw.go.jp/stf/covid-19/vaccine.html.
4. Kayukawa S, Nanya K, Morita M, Ina K, Ota Y, Hasegawa S. Spike antibody titers evaluation after a 2-dose regimen of BNT162b2 vaccination in healthcare workers previously infected with SARS-CoV-2. Microbiol Spectr (2021) 9:e0103621. doi: 10.1128/Spectrum.01036-21
5. Engelke K, Museyko O, Wang L, Laredo JD. Quantitative analysis of skeletal muscle by computed tomography imaging-state of the art. *J Orthop Translat* (2018) 15:91–103. doi: 10.1016/j.jot.2018.10.004

6. Long DE, Villasante Tezanos AG, Wise IN, Kern PA, Bamman MM, Peterson CA, et al. A guide for using NIH image J for single slice cross-sectional area and composition analysis of the thigh from computed tomography. *PloS One* (2019) 14: e0211629. doi: 10.1371/journal.pone.0211629

7. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant* (2013) 48:452–8. doi: 10.1038/bmt.2012.244

8. Zuckerman JN. The importance of injecting vaccines into muscle. Different patients need different needle sizes. *BMJ* (2000) 321:1237–8. doi: 10.1136/bmj.321.7271.1237

9. Ng JY. Inadvertent subcutaneous injection of COVID-19 vaccine. *Postgrad Med J* (2021) 97:400. doi: 10.1136/postgradmedj-2021-139870

10. Golekoh MC, Hu S, Norman AM, Horn PS, Brady RC, Wong BL. Comparison of the immunogenicity of intramuscular versus subcutaneous administration of trivalent inactivated influenza vaccine in individuals with neuromuscular diseases. *J Child Neurol* (2013) 28:596–601. doi: 10.1177/0883073813480243

11. Havers F, Fry A, Peacock G, Finelli L. Influenza vaccination and treatment in children with neurologic disorders. *Ther Adv Vaccines* (2014) 2:95–105. doi: 10.1177/2051013613519217

12. Nakamura K, Kosano M, Sakai Y, Saito N, Takazawa Y, Omodaka T, et al. Case of bullous pemphigoid following coronavirus disease 2019 vaccination. *J Dermatol* (2021) 48:e606–e7. doi: 10.1111/1346-8138.16170

13. Di Resta C, Ferrari D, Viganò M, Moro M, Sahetta E, Mineva M, et al. The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination-an analysis of serological response and side effects. *Vaccines (Basel)* (2021) 9:522. doi: 10.3390/vaccines9050522